FCGR1A and B-cell non-Hodgkin lymphoma: Here, we demonstrate that iPSC-derived NK (iNK) cells expressing CD64/16A when in the presence of, or armed with, therapeutic mAbs mediate potent ADCC against B cell lymphoma cells.